Primary results from the Phase II ARASEC trial show that NUBEQA ® (darolutamide) plus androgen deprivation therapy (ADT) showed a statistically significant improvement in progression-free survival ...

Bayer has filed for approval to extend the use of its prostate cancer therapy Nubeqa as it tries to achieve labelling parity with rival drugs from Pfizer/Astellas and Johnson & Jonson, and fulfil its ...

These results build on existing data from the ARASENS trial, which show that NUBEQA plus ADT and docetaxel compared to ADT and docetaxel significantly reduces the risk of death in patients with mHSPC ...

Nubeqa (darolutamide) is a brand-name oral tablet prescribed for certain types of prostate cancer in adults. As with other drugs, darolutamide may cause side effects, such as fatigue, nausea, and rash ...

Bayer has won a key FDA approval to extend the use of its prostate cancer therapy Nubeqa, as it tries to claim market share from rival drugs and fulfil its aim of building the drug into a €3 billion ...

Nubeqa (darolutamide) is a prescription drug that’s used to treat certain types of prostate cancer in adults. Nubeqa comes as an oral tablet. Nubeqa contains the active ingredient darolutamide. (An ...

Patients treated with Nubeqa were less likely to develop disease metastasis or discontinue treatment 6 to 18 months after ARI course start compared to Xtandi or Erleada, according to data presented at ...

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer today announced the U.S. Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) and granted Priority Review for the oral ...

If you have prostate cancer, your health care provider may have told you about a medicine called Nubeqa (darolutamide). The FDA approved Nubeqa in 2019. It is commonly used to treat prostate cancer ...